| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Research Abstract |
An immunotherapy using autoγδT lymphocyte was conducted in patients with extrahepatic metises from hepatocellular carcinoma. In addition, an adjuvant therapy using combination of Gemcitabine and autoγδT lymphocyte immunotherapy was conducted for postoperative patients with intrahepatic cholangiocarcinoma, as a primary liver cancer like hepatocellular carcinoma. Three patients were enrolled in the former setting and 8 patients were enrolled in the latter setting. The safety of the therapy was confirmed, but the benefit in terms of progression-free survival was unclear. Because of the scarcity of the included patients, further enrollment of patients and follow-up will be necessary.
|
